Janux Therapeutics (JANX) Other Non-Current Assets (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Other Non-Current Assets data on file, last reported at $816000.0 in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $816000.0, down 70.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $816000.0 (down 70.77% YoY), and the FY2025 annual result was $2.6 million, down 9.57% from the prior year.
• Other Non-Current Assets fell to $816000.0 in Q1 2026 per JANX's latest filing, from $2.6 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $2.9 million in Q4 2024 and troughed at $337000.0 in Q1 2022.
• A 5-year average of $1.5 million and a median of $816000.0 in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Assets soared 482.86% in 2022, then plunged 70.77% in 2026.
• A 5-year view of Other Non-Current Assets shows it stood at $816000.0 in 2022, then changed by 0.0% to $816000.0 in 2023, then soared by 253.43% to $2.9 million in 2024, then slipped by 9.57% to $2.6 million in 2025, then sank by 68.71% to $816000.0 in 2026.
• Business Quant data shows JANX's Other Non-Current Assets at $816000.0 in Q1 2026, $2.6 million in Q4 2025, and $2.6 million in Q3 2025.